Biotech · Public company · Boston, MA, US

Rapport Therapeutics, Inc.

Ticker RAPP · SEC CIK 0002012593

Track this companyFree. Adds Rapport Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials53 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresPHASE3 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07594119 · fetched Nov 12, 2026
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1PHASE3 · RECRUITING · started Jun 5, 2026ClinicalTrials.gov NCT07563881 · fetched Nov 12, 2026
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresPHASE2 · RECRUITING · started Dec 15, 2025ClinicalTrials.gov NCT07219407 · fetched Nov 12, 2026
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderPHASE2 · COMPLETED · started Jul 25, 2025ClinicalTrials.gov NCT07046494 · fetched Nov 12, 2026
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal EpilepsyPHASE2 · COMPLETED · started Oct 10, 2024ClinicalTrials.gov NCT06377930 · fetched Nov 12, 2026